The study was conducted in transplant-ineligible and failure patients with relapsed/refractory classical Hodgkin Lymphoma whose disease had progressed on or after treatment with brentuximab vedotin. Complete remission was achieved in 21 percent of patients in the study.
http://ift.tt/15VwJ0P
http://ift.tt/15VwJ0P
No comments:
Post a Comment